Specialists from the Gdańsk Medical University’s I Clinic of Cardiology successfully implemented the A-Flux device in a patient with coronary microvascular dysfunction—a condition affecting small coronary vessels not visible in standard coronary angiography. This makes the GUMed team the second in the world to perform this procedure.Refractory angina affects patients with chronic coronary syndrome whose symptoms persist despite optimal pharmacotherapy and interventional treatments. The A-Flux device is a minimally invasive, self-expanding flow reducer implanted in the coronary sinus. It increases venous pressure, redistributes blood flow to previously underperfused areas of the heart, improves microcirculation, and reduces angina symptoms. The procedure is performed via the internal jugular vein under local anesthesia, and patients are usually discharged the next day, with symptom improvement often occurring within weeks.Prof. Miłosz Jaguszewski emphasized that this therapy can benefit patients with microvascular angina, who otherwise have no interventional options. The procedure at GUMed was also a pioneering “compassionate use” case, providing access to advanced therapy when other treatments fail.The implantation was performed by Prof. Miłosz Jaguszewski (operator), Dr. Grzegorz Żuk (coordinator), and Italian expert Francesco Giannini, highlighting strong international collaboration. GUMed continues to train and support other centers in Northern Poland in implementing this cutting-edge therapy.
Source:Gdańsk Medical University
About the Author
